SBFM vs. EVLO, EVFM, SPRC, BLPH, ADTX, CMRA, SXTC, GRI, ATHX, and APVO
Should you be buying Sunshine Biopharma stock or one of its competitors? The main competitors of Sunshine Biopharma include Evelo Biosciences (EVLO), Evofem Biosciences (EVFM), SciSparc (SPRC), Bellerophon Therapeutics (BLPH), Aditxt (ADTX), Comera Life Sciences (CMRA), China SXT Pharmaceuticals (SXTC), GRI Bio (GRI), Athersys (ATHX), and Aptevo Therapeutics (APVO). These companies are all part of the "pharmaceutical preparations" industry.
Sunshine Biopharma (NASDAQ:SBFM) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.
42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 14.7% of Sunshine Biopharma shares are owned by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Sunshine Biopharma has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500.
Sunshine Biopharma has higher revenue and earnings than Evelo Biosciences. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.
Evelo Biosciences has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.70%. Evelo Biosciences' return on equity of 0.00% beat Sunshine Biopharma's return on equity.
Evelo Biosciences received 169 more outperform votes than Sunshine Biopharma when rated by MarketBeat users. However, 100.00% of users gave Sunshine Biopharma an outperform vote while only 60.50% of users gave Evelo Biosciences an outperform vote.
In the previous week, Evelo Biosciences' average media sentiment score of 0.32 beat Sunshine Biopharma's score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the news media.
Sunshine Biopharma presently has a consensus target price of $260.00, indicating a potential upside of 26,162.63%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than Evelo Biosciences.
Summary
Sunshine Biopharma beats Evelo Biosciences on 9 of the 16 factors compared between the two stocks.
Get Sunshine Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBFM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sunshine Biopharma Competitors List
Related Companies and Tools
